Literature DB >> 8923592

Antinuclear antibody in systemic sclerosis (scleroderma).

Y Okano1.   

Abstract

The presence of autoantibodies to intracellular molecules is the hallmark immunologic finding of SSc. Recent sophisticated methods have contributed to characterization of unidentified antigens of ANA in sera from patients with SSc. Antibodies to RNA polymerases are the third major SSc-specific ANA, in addition to anti-topo I and anticentromere antibodies, and it is now possible to identify over 85% of SSc patients. These antibodies have proved helpful in diagnosis of this disease. An immunogenetic predisposition to synthesis of the ANAs has been unveiled. Both antigen-driven and molecular mimicry hypotheses have been proposed for ANA production in SSc. Although the role of ANAs in the pathogenesis of SSc is not yet known, it is logical to assume that the origin of ANAs is linked to the causes of this disease because each antibody is associated with its own unique constellation of clinical features.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923592     DOI: 10.1016/s0889-857x(05)70297-0

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  28 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

3.  Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis.

Authors:  Victoria K Shanmugam; Donna R Swistowski; Nicole Saddic; Hong Wang; Virginia D Steen
Journal:  Clin Rheumatol       Date:  2011-05-27       Impact factor: 2.980

4.  Evaluation of liver function tests in scleroderma patients.

Authors:  Gehan Ibrahim Abdelrazek Salem; Awni Ali Abdulrahman
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

5.  Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis.

Authors:  Franca Majone; Silvia Olivieri; Franco Cozzi; Anna Montaldi; Marta Tonello; Maria Serena Visentin; Luca Ciprian; Amelia Ruffatti
Journal:  Rheumatol Int       Date:  2008-12-03       Impact factor: 2.631

6.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

Review 7.  Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

Authors:  Minoru Satoh; Monica Vázquez-Del Mercado; Edward K L Chan
Journal:  Mod Rheumatol       Date:  2009-03-10       Impact factor: 3.023

8.  B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.

Authors:  Noriko Asano; Manabu Fujimoto; Norihito Yazawa; Senji Shirasawa; Minoru Hasegawa; Hitoshi Okochi; Kunihiko Tamaki; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

9.  Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis.

Authors:  Shihoko Okazaki; Fumihide Ogawa; Yohei Iwata; Toshihide Hara; Eiji Muroi; Kazuhiro Komura; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Shinichi Sato
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

10.  Increased circulating fibrinogen-like protein 2 in patients with systemic sclerosis.

Authors:  Koichi Yanaba; Yoshihide Asano; Shinji Noda; Kaname Akamata; Naohiko Aozasa; Takashi Taniguchi; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Hayakazu Sumida; Yoshihiro Kuwano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2012-09-16       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.